Electric Medicine, The First Crispr Baby Gets Edits, Court Rules For HHS In 340B Case

Hey all,

Happy Monday! I have been fascinated by all of the work being produced focused on electric fields and pulses. The more I personally see the positive effects from acupuncture therapy and read about the success of TMS from my buddy Owen Muir, I’m excited to see what ailments we can treat by rewiring the body's circuits. Enjoy the rundown! 

Jacob Brody (Co-Founder & CEO, ZorroRX)

(Wall Street Journal) Electricity as a Medical Treatment

Scientists and biotech companies are increasingly exploring electricity as a therapeutic tool, with electric fields and pulses showing promise in treating diseases like cancer and rheumatoid arthritis. Technologies from firms like Novocure and SetPoint Medical harness the body’s electrical properties to disrupt cancer cell division or reduce inflammation via nerve stimulation, potentially offering non-pharmaceutical alternatives with fewer side effects. As clinical trials report extended survival in glioblastoma patients and improved symptoms in autoimmune disorders, experts believe the next decade could usher in a new era of electrical medicine. This growing field echoes how treatments like TMS for depression and acupuncture for pain tap into the body's bioelectrical systems to restore balance and health. Full Article

(Ground Truths) First In Vivo CRISPR 2.0 Genome Editing in a Human 

Eric Topol walks us through a groundbreaking case report that details the first use of in vivo CRISPR 2.0 base editing to correct a pathogenic gene mutation in a living human—an infant named KJ Muldoon with a fatal urea-cycle disorder. Unlike earlier CRISPR therapies that disrupt rather than repair genes, this new approach directly fixes the mutation inside the body using mRNA-delivered base editors, potentially laying the groundwork for scalable, less invasive treatments for thousands of rare and common genetic diseases. This marks a historic shift toward personalized, precision genetic medicine. Full Article.

(Endpoints News) Court Ruling on 340B Rebate Models

A federal judge ruled that the U.S. Department of Health and Human Services (HHS) can require drugmakers to get approval before changing how they offer discounts through the 340B program. The decision is a major win for HHS and its Health Resources and Services Administration (HRSA), which argued that letting companies unilaterally switch to rebate-based discounts could disrupt a program that’s been in place for over 30 years to help hospitals and clinics serve low-income patients. Drugmakers like Eli Lilly, Sanofi, Novartis, and Bristol Myers Squibb say the program is being abused and want more control over how discounts are applied, but the court largely backed the government’s right to oversee those changes—though the pharma companies might just be bummed they couldn’t lock in a six-year rebate window while they were at it. Full Article.